Understand the source comparison
Vasoactive Intestinal Peptide: Research Applications Comparison
Autoimmune disease (EAE, CIA) Treg induction, Th1/Th17 suppression via VPAC1 Reduced disease severity scores, decreased CNS infiltrates, lower joint inflammation Requires daily dosing during disease induction; half-life necessitates continuous presence during
No winner is assigned.
This page preserves a source comparison for education. It does not add a rating, recommendation or clinical judgment.
- Autoimmune disease (EAE, CIA)
- Treg induction, Th1/Th17 suppression via VPAC1
- Reduced disease severity scores, decreased CNS infiltrates, lower joint inflammation
- Requires daily dosing during disease induction; half-life necessitates continuous presence during immune priming
- VIP demonstrates consistent efficacy across autoimmune models but short half-life limits translational feasibility without analog development
- Sepsis/endotoxemia
- Macrophage M1-to-M2 polarization, reduced TNF-alpha/IL-6
- Improved survival, lower serum cytokines, preserved organ function
- Timing relative to LPS challenge is critical. Pretreatment more effective than post-treatment
- VIP shows promise in early intervention scenarios but therapeutic window is narrow in acute inflammatory settings
- Gastrointestinal motility
- Smooth muscle relaxation via cAMP/PKA, reduced intracellular calcium
- Delayed gastric emptying, increased intestinal transit time
- Dose-response is biphasic. Low doses stimulate secretion, high doses inhibit motility
- VIP remains the gold standard for enteric nervous system research but route of administration significantly affects regional distribution
- Circadian rhythm disruption
- VPAC2-mediated SCN synchronization
- Restored rhythm coherence, normalized phase angle
- Long-term protocols require stable dosing schedules; mice lacking VIP provide strong genetic controls
- VIP is irreplaceable in circadian neuroscience but experimental design must account for its rapid clearance
- Neuroprotection (ischemia, excitotoxicity)
- Reduced microglial activation, enhanced BDNF expression
- Decreased infarct volume, preserved neuronal density
- Blood-brain barrier penetration is limited; intracerebroventricular delivery often required
- VIP shows neuroprotective capacity in injury models but delivery constraints reduce clinical translation potential